ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

JMKX000189

A development code.

Its studies are mostly in Lupus Erythematosus, Systemic, led by 2 companies.

Furthest: phase 2, since Jul 21, 20232 company-led studies, 2 open or runningNext primary completion: Jun 20, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jemincare11 open or runningphase 2since Jul 21, 2023Jul 21, 2023none ahead
Shanghai Jeyou Pharmaceuticalits history only11 open or runningphase 1since May 6, 2026May 6, 2026Jun 20, 2027phase 1 · NCT07601386

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jemincare only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2023First study: phase 2 study in Lupus Erythematosus, SystemicFirst studyNCT05967520 · 48 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Jemincare leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05967520Lupus Erythematosus, Systemic · China2RecruitingMay 202548

How it is read

Names in the registry

  • “JMKX000189”, 2 entries

Codes read as this program: JMKX000189.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.